| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 08/27/2008 | CN100413539C The use of 5ht4 receptor antagonists in the prophylaxis or treatment of certain cardiovascular conditions |
| 08/27/2008 | CN100413538C Remedy for corneal failure |
| 08/27/2008 | CN100413532C Medicine composition for anti consumptive disease |
| 08/27/2008 | CN100413513C Medication for treating neonatal jaundice, and method of use |
| 08/27/2008 | CN100413512C Use of ginkgo biloba extracts in order to promote muscle mass to the detriment of fatty mass |
| 08/27/2008 | CN100413492C Solid pharmaceutical compositions containing miltefosine for oral administration in the treatment of leishmaniasis |
| 08/26/2008 | US7417050 Cognition activators; Alzheimer's disease; attention deficit disorders; Parkinson's disease; Huntington's disease; neurodegenerative disease |
| 08/26/2008 | US7417049 Furyl compounds |
| 08/26/2008 | US7417046 Inhibiting the proteolytic activity of cathepsin S; 1-[4-(5-Chloro-1H-indol-3-yl)-piperazine-1-yl]-3-[5-methanesulfonyl-3-(4-trifluoromethyl-phenyl)-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl]-propan-2-ol; antiarthritic agent; autoimmune disease: lupus, rheumatoid arthritis, and asthma |
| 08/26/2008 | US7417043 3-substituted 4-(phenyl-N-alkyl)-piperazine derivatives; central nervous system disorders; dualistic dopaminergic action profile with antagonist-like effects on brain neurochemistry and mild agonist-like effects on normal behavior, induce inhibition of behavior in hyperactivity; oral bioavailability |
| 08/26/2008 | US7417039 Use of substituted azetidinone compounds for the treatment of sitosterolemia |
| 08/26/2008 | US7417029 Using an interleukin-1 beta converting enzyme inhibitor pro-drug to treat apoptosis-, interferon-gamma inducing factor or interferon-gamma inducing diseases; antiinflammatory and -proliferative agents; autoimmune/degenerative disesesdiseases |
| 08/26/2008 | US7417024 template-fixed beta -hairpin peptidomimetics incorporating a template-fixed chain of 7 or 11 alpha -amino acid residues which, depending on their position in the chain, are Gly, or Pro, or of certain types; inhibitors of various serine proteases such as trypsin, human cathepsin G, and thrombin |
| 08/26/2008 | US7416885 Proliferation factor is obtained from the UCHT1 rat thyroid cell line, or a fragment, analogue or derivateve |
| 08/26/2008 | US7416858 Forming a convalent conjugate of a peptide, removing X2 or a saccharyl subunit thereof from peptide forming a truncated glycan; contacting truncated glycan with glycosyltransferase and modified sugar donor under conditions suitable for glycosyltransferase to transfer a modified sugar moiety |
| 08/26/2008 | US7416730 Derivatives of the IL-2 receptor gamma chain, their production and use |
| 08/26/2008 | US7416726 Cytotoxicity; therapeutic antibody |
| 08/26/2008 | CA2432129C Pyrazole compounds useful as protein kinase inhibitors |
| 08/26/2008 | CA2410446C Esmolol formulation |
| 08/26/2008 | CA2397961C Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors |
| 08/26/2008 | CA2333669C 17.beta.-amino and hydroxylamino-11.beta.-arylsteroids and their derivatives having agonist or antagonist hormonal properties |
| 08/26/2008 | CA2274825C Substituted nitrogen containing heterocycles as inhibitors of p38 protein kinase |
| 08/26/2008 | CA2239780C A process for regulating vagal tone |
| 08/26/2008 | CA2208981C Novel trienoic retinoid compounds and methods |
| 08/26/2008 | CA2152401C Synergising association having an antagonist effect on nk1 and nk2 receptors |
| 08/21/2008 | WO2008100328A2 METHODS AND COMPOSITIONS FOR TARGETING gC1qR/p32 |
| 08/21/2008 | WO2008099913A1 Therapeutic agent comprising antibody capable of specifically binding to human hmgb-1 as active ingredient |
| 08/21/2008 | WO2008099912A1 5ht4 receptor antagonist |
| 08/21/2008 | WO2008099907A1 Therapeutic agent for urinary excretion disorder |
| 08/21/2008 | WO2008099883A1 Therapeutic agent for liver cancer |
| 08/21/2008 | WO2008099874A1 Pharmaceutical composition comprising pyrazine derivative, and method of using pyrazine derivative in combination |
| 08/21/2008 | WO2008099829A1 Method for formation of intestinal adhesion in experimental animal, method for production of experimental animal having intestinal adhesion, method for screening of intestinal adhesion-preventing agent, and intestinal adhesion-preventing agent |
| 08/21/2008 | WO2008099615A1 Pharmaceutical composition containing fine particle oil-based suspension |
| 08/21/2008 | WO2008099544A1 Novel lactic acid bacteria |
| 08/21/2008 | WO2008025787A3 Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases |
| 08/21/2008 | US20080201789 Variants and exons of the glyt1 transporter |
| 08/21/2008 | US20080200674 Anticoagulants; cardiovascular disorders; atherosclerosis; antiarthritic agents;Alzheimer's disease; anticancer agents |
| 08/21/2008 | US20080200646 and cerebral ischemia and or the onset of systemic inflammatory response particularly when associated with a surgical procedure(especially cardiothoracic surgery; kit comprising a dry lyophilized kallikrein inhibitor DX88 in a hermetically sealed container (rather than aprotinin) |
| 08/21/2008 | US20080200555 Use of norepinephrine reuptake inhibitors for the treatment of tic disorders |
| 08/21/2008 | US20080200548 N-Acetylcysteine Amide (Nac Amide) for Treatment of Oxidative Stress Associated with Infertility |
| 08/21/2008 | US20080200547 Highly Purified Ethyl EPA and Other EPA Derivatives |
| 08/21/2008 | US20080200508 Controlled extended release of serotonin receptor anatagonist; alleviating sleep apnea; kits |
| 08/21/2008 | US20080200505 Piperidines for the Treatment of Chemokine Mediated Diseases |
| 08/21/2008 | US20080200494 Imidazopyridine Derivatives |
| 08/21/2008 | US20080200486 Combination Of Organic Compounds |
| 08/21/2008 | US20080200484 Pharmaceutical Compositions Comprising A Multifunctional Phosphodiesterase Inhibitor and An Adenosine Uptake Inhibitor |
| 08/21/2008 | US20080200474 Novel flunarizine salt forms and methods of making and using the same |
| 08/21/2008 | US20080200447 Neurotherapeutic Compositions and Method |
| 08/21/2008 | US20080200444 Soluble epoxide hydrolase inhibitors |
| 08/21/2008 | US20080200436 Antiangiogenic and/or vascular permeability reducing effect; cancer, solid tumors; kits |
| 08/21/2008 | US20080200432 Fiber-Treating Agent |
| 08/21/2008 | US20080200417 High efficiency encapsulation of charged therapeutic agents in lipid vesicles |
| 08/21/2008 | US20080200413 Oligonucleotide sequences which bind biomolecules such as peptides; selectively bind coagulation factors, E2F family members, Ang1 or Ang2; hydrophobic molecules and extracellular proteins for diagnosing and treating cardiovascular disorders in mammals |
| 08/21/2008 | US20080200410 Kits containing primers or probes; amplification and/or hybridization; early diagnosis of neoplastic disease |
| 08/21/2008 | US20080200408 Isolated recombinant nucleic acids; expression constructs; stably transformed or transfected host cells; sodium channel antagonistic analgesic agents; side effect reduction |
| 08/21/2008 | US20080200407 Suppress the immunoreactivity of a CpG motif and preventing and treating immune-mediated diseases such as arthritis |
| 08/21/2008 | US20080200391 Stimulating differentiation in growth of osteoblasts and osteoclasts; wound healing of bone fractures and de novo bone formation; osteoporosis; bone cancer treatment; polynucleotide encoding polypeptide; genetic engineering |
| 08/21/2008 | US20080200389 Rank-ligand-induced sodium/proton antiporter polypeptides |
| 08/21/2008 | US20080199917 Using vector comprising early gene modifications as genetic transfer element in gene therapy; gnentic vaccines |
| 08/21/2008 | US20080199896 Using inhibitors of target of rapamycin (TOR) gene products as therapeutic agent in treatment of cardiovascular disorders |
| 08/21/2008 | US20080199865 Using allelic variation in interleukin-1RN variable number of tandem repeats as diagnostic/prognostic indicator of decrease cell division and aging characteristics |
| 08/21/2008 | US20080199529 Nanoparticle delivery vehicle |
| 08/21/2008 | US20080199513 Systems and methods for preparing autologous fibrin glue |
| 08/21/2008 | US20080199491 vaccine containing antigen and non-liquid adjuvants ; implantable pellet, capsule, tablet, powder or aerosol |
| 08/21/2008 | US20080199478 Combinations of Immunosupressive Agents for the Treatment or Prevention of Graft Rejections |
| 08/21/2008 | US20080199472 Using secretory leukocyte protease inhibitor (SLPI) to identify modulators for treatment and prevention of tumor migration |
| 08/21/2008 | US20080199471 Optimized cd40 antibodies and methods of using the same |
| 08/21/2008 | US20080199469 Using A20 binding inhibitor of NF- kappa B (ABIN) to stabilize MEK kinase and treat and/or prevent inflammatory diseases |
| 08/21/2008 | US20080199466 Activation-inducible lymphocyte immunomediatory molecule specific immunoglobulin for treating and preventing inflammatory, autoimmune, ischemic, transplant and/or allergic disorders |
| 08/21/2008 | US20080199465 Accelerated lymphocyte homing agent such as fingolimod and one or more compounds selected from an antibody to the IL-2 receptor, an immunosuppressive macrocyclic lactone and a soluble human complement inhibitor |
| 08/21/2008 | US20080199463 Method for treating multiple myeloma |
| 08/21/2008 | US20080199442 Gene linked to control elements capable of directing in vivo transcription and translation; systemic delivery of erythropoietin |
| 08/21/2008 | US20080199433 Complementing cell lines |
| 08/21/2008 | US20080199431 Self-Assembling Membranes And Related Methods Thereof |
| 08/21/2008 | US20080199428 Administering deferasirox, 4-(3,5-Bis-(2-hydroxyphenyl)-(1,2,4)-triazol-1-yl)benzoic acid, interferon and ribavirin; hepatitis and non-alcoholic steatohepatitis |
| 08/21/2008 | US20080199424 Mart-1 t cell receptors |
| 08/21/2008 | US20080199405 Polypeptide comprising a soluble Mycobacterium tuberculosis antigen; vaccines |
| 08/21/2008 | US20080199399 Interfacing Nanostructures to Biological Cells |
| 08/21/2008 | DE60037007T2 Angereicherte zentralnervensystem-zellpopulationen Enriched cns-cell populations |
| 08/21/2008 | CA2677905A1 Pharmaceutical composition comprising pyrazine derivatives and neuraminidase inhibitors for treating influenza infections |
| 08/21/2008 | CA2677842A1 Pharmaceutical composition comprising microparticle oily suspension |
| 08/21/2008 | CA2677769A1 Therapeutic agent for urinary excretion disorder |
| 08/20/2008 | EP1959013A1 Human circulating virus inhibitory peptide (VRIP) and its use |
| 08/20/2008 | EP1958966A2 Methods for modulating T cell responses by manipulating a common cytokine receptor gamma chain |
| 08/20/2008 | EP1958956A2 Peptidomimetic protease inhibitors |
| 08/20/2008 | EP1958642A1 Regulation of cell growth by MUC1 |
| 08/20/2008 | EP1958503A2 Expression of secreted human alpha-fetoprotein in transgenic animals |
| 08/20/2008 | EP1957079A1 Use of a combination of ethynylestradiol and chlormadinone acetate for the treatment of mood changes |
| 08/20/2008 | EP1957072A1 Treatment of asthma and copd using triple-combination therapy |
| 08/20/2008 | EP1896077A4 Methods and compositions for the prevention and treatement of inflammatory disease |
| 08/20/2008 | EP1567523B1 Indolyl derivatives |
| 08/20/2008 | EP1509618B1 Autoimmune conditions and nadph oxidase defects |
| 08/20/2008 | EP1509521B1 1h-imidazo[4,5-c]quinoline derivatives for the treatment of protein kinase dependent diseases |
| 08/20/2008 | EP1499284B1 Biologically active compounds for the modification of bodily odours |
| 08/20/2008 | EP1482976B1 A preparation and method for weight reduction |
| 08/20/2008 | EP1482935B1 Thiazole and oxazole derivatives which modulate ppar activity |
| 08/20/2008 | EP1461445B1 Glycoprotein remodeling using endoglycanases |
| 08/20/2008 | EP1459765B1 6-fluorobicyclo 3.1.0 hexane derivatives |
| 08/20/2008 | EP1456203B1 Ethylene diamine derivatives and their use as orexin-receptor antagonists |
| 08/20/2008 | EP1451202B1 Aryl fused azapolycyclic compounds |